Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
暂无分享,去创建一个
L. Bullinger | K. Döhner | R. Schlenk | H. Döhner | V. Gaidzik | P. Paschka | M. Heuser | F. Thol | A. Ganser | K. Götze | A. Benner | M. Lübbert | S. Cocciardi | F. Rücker | E. Koller | A. Dolnik | A. Corbacioglu | Anika Schrade | N. Jahn | D. Weber | D. Wellnitz | T. Schröder | J. Herzig | Tobias Terzer | E. Panina | E. Sträng | F. Rücker | Nikolaus Jahn | Thomas Schröder
[1] W. Hiddemann,et al. The clinical mutatome of core binding factor leukemia , 2020, Leukemia.
[2] B. Ebert,et al. Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1) , 2019, Leukemia.
[3] L. Bullinger,et al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. , 2019, Blood.
[4] Christopher A. Miller,et al. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential , 2018, Nature Communications.
[5] Karl W. Kroll,et al. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia , 2017, Leukemia.
[6] Eunhee Kim,et al. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia , 2017, Nature Communications.
[7] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[8] Heather L. Mulder,et al. The genomic landscape of core-binding factor acute myeloid leukemias , 2016, Nature Genetics.
[9] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[10] W. Hiddemann,et al. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation , 2016, Nature Communications.
[11] O. Abdel-Wahab,et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. , 2016, Blood.
[12] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[13] W. Kahr,et al. Dynamin 2‐Dependent Endocytosis is Required For Normal Megakaryocyte Development , 2015, Blood.
[14] Jun Huang,et al. The Human SRCAP Chromatin Remodeling Complex Promotes DNA-End Resection , 2014, Current Biology.
[15] T. Haferlach,et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome , 2014, Leukemia.
[16] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[17] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[18] K. Döhner,et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. , 2009, Blood.
[19] A. Sorkin,et al. Endocytosis and signalling: intertwining molecular networks , 2009, Nature Reviews Molecular Cell Biology.
[20] Karl Pearson F.R.S.. X. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling , 2009 .
[21] C. Bloomfield,et al. Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study , 2008 .
[22] Thomas A Gerds,et al. Efron‐Type Measures of Prediction Error for Survival Analysis , 2007, Biometrics.
[23] Harald Binder,et al. Assessment of survival prediction models based on microarray data , 2007, Bioinform..
[24] C. Bloomfield,et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] H. Dombret,et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) , 2006, Leukemia.
[26] C. Bloomfield,et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Thomas Augustin,et al. Bradley-Terry-Luce models to incorporate within-pair order effects: representation and uniqueness theorems. , 2004, The British journal of mathematical and statistical psychology.
[28] K. Döhner,et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Shiekhattar,et al. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. , 2003, Molecular cell.
[30] J. Reilly,et al. Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias , 2003, British journal of haematology.
[31] J. Downing,et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. , 2002, Cancer cell.
[32] N. Jenkins,et al. Mga, a dual‐specificity transcription factor that interacts with Max and contains a T‐domain DNA‐binding motif , 1999, The EMBO journal.
[33] Lisa Garrett,et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia , 1999, Nature Genetics.
[34] Y. Ito,et al. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[35] R. Tibshirani. The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.
[36] M. Akritas. Nearest Neighbor Estimation of a Bivariate Distribution Under Random Censoring , 1994 .
[37] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.
[38] F. Ferrara,et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. , 2006, Blood.
[39] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .